Business
OS Therapies Enters into Warrant Inducement Agreements
$7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet proceeds to fund OST-HER2 regulatory approval submissions, commercial preparation activities and preparations for OS Animal Health proposed spinoff transactionNew York, New York--(Newsfile Corp. - January 12, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in listeria-based cancer...
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"$7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027","length":92,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"All nine investors that were offered agreed to participate","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net proceeds to fund OST-HER2 regulatory approval submissions, commercial preparation activities and preparations for OS Animal Health proposed spinoff transaction","length":163,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":313,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - January 12, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in listeria-based cancer immunotherapies, today announced that it launched a warrant exercise inducement and exchange offer to nine accredited investors (the "Holders") that hold common stock purchase warrants issued in connection with the Company's previous third quarter 2025 warrant exercise inducement and exchange offers (the "Existing Warrants"). All nine Holders offered have entered into inducement offer letter agreements with the Company to exercise or pre-fund for cash all of their Existing Warrants, providing a total of $7.53 million in gross proceeds to the Company. A description of the material terms of the transaction is included in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission.","length":941,"tagName":"p"},{"type":"text","content":"Ceros Capital Markets, a division of Ceros Financial Services, Inc., acted as the exclusive warrant solicitation agent for the transaction.","length":139,"tagName":"p"},{"type":"text","content":"The gross proceeds raised provide the Company runway into 2027, and the Company expects to use the net proceeds to support regulatory filings and commercial preparation activities related for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the U.S., UK and European Union (the "Human Metastatic Osteosarcoma Program"), to provide funding for the Company's wholly owned subsidiary OS Animal Health's proposed spinoff transaction preparations, and general corporate purp...